

# Genes and pathways modulated during Guillain-Barré Syndrome

Raulzito Fernandes Moreira<sup>1</sup>, Paulo Ricardo Porfírio do Nascimento<sup>2</sup>, Glória Regina de Góis Monteiro<sup>3</sup>, Mario Emilio Teixeira Dourado Junior<sup>3</sup>, Selma Maria Bezerra Jeronimo<sup>3</sup>, João Paulo Matos Santos Lima<sup>4</sup>

*1 PROGRAMA DE PÓS-GRADUAÇÃO EM BIOTECNOLOGIA DOS RECURSOS NATURAIS, UNIVERSIDADE FEDERAL DO CEARÁ*

*2 INSTITUTO DE MEDICINA TROPICAL DO RIO GRANDE DO NORTE, UFRN.*

*3 INSTITUTO DE MEDICINA TROPICAL DO RIO GRANDE DO NORTE, UFRN*

*4 PROGRAMA DE PÓS-GRADUAÇÃO EM BIOINFORMÁTICA, UFRN*

## Abstract

Guillain-Barré syndrome (GBS) is an acute polyradiculoneuropathy, monophasic, and since the eradication of poliomyelitis is the principal cause of paralysis in the world. This syndrome seems to have an autoimmune component characterized, in part, by molecular mimicry with production of antibodies that causes severe damage to peripheral nerves. Such damage results in symptoms, which include acute flaccid paralysis. About 30% of the cases need respiratory assistance. GBS cases is usually preceded by infection agents, such as *Campylobacter jejuni* and viral infections. It seems that the pathogenesis of *C. jejuni* in GBS is associated with anti-gangliosides antibodies, which cross react with gangliosides present in the nerve axolemma, mainly in the peripheral nerves. Hence, the present study aimed to analyze transcriptomic libraries from patients with GBS, diagnosed with the different subtypes (demyelinating, axonal and Miller-Fisher), in order to identify genes and key pathways related to GBS development and potential target for modulation. For this, 24 libraries were obtained from 12 Brazilian patients diagnosed with GBS (6 from demyelinating subtype, 4 from axonal form and 2 from Miller-Fisher form), in two distinct phases, symptomatic/acute phase and after complete recovery. The quality analysis, alignment, assembly and global gene expression were performed using FastQC, Bowtie, TopHat, Cufflinks (Cuffmerge) HTSeq and edgeR. Approximately 2000 genes were differentially expressed between symptomatic and the recovery phase ( $p < 0.01$  and log fold change 1.5). Transcript annotation based on GO and KEGG terms showed changes in expression of genes related to inflammation, as TNF signaling pathway, toll-like and NOD-like receptor signaling pathways. Also, pathways related to neurodegenerative, autoimmune and infectious diseases were enriched during symptomatic phase when compared to recovery phase. These results are in accordance to other previous studies and provide an overview of possible responses during the course of GBS.

Funding: CNPq, NIH, FUNCAP, CAPES.